+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Palliative treatment of symptomatic benign prostatic hyperplasia by permanent urethral stent (Ultraflex, Boston Scientific) in high surgical risk patients



Palliative treatment of symptomatic benign prostatic hyperplasia by permanent urethral stent (Ultraflex, Boston Scientific) in high surgical risk patients



Progres en Urologie 17(5): 954-959



To evaluate the medium-term and long-term results of treatment of symptomatic benign prostatic hyperplasia (BPH) by permanent transprostatic urethral stenting in high surgical risk patients. Single-centre retrospective study on 19 consecutive patients with a mean age of 79.5 years (range: 61-96) treated by nitinol permanent urethral stent (Boston Scientific Corp.) from December 1995 to July 2006 for bladder neck obstruction. All patients presented a major contraindication (ASA III or IV) to immediate conventional surgical management. Stenting was performed under endourethral Xylocaine gel local anaesthesia. Fourteen patients presented acute urinary retention and 4 had chronic obstructive renal failure. One patient with an indwelling catheter had a history of recurrent acute prostatitis. The functional results were assessed by resumption of voiding, determination of post-voiding residual volume, serum creatinine and presence or absence of symptomatic urinary tract infection. The anatomical assessment was performed by voiding and retrograde cystourethrography and urethral endoscopy. This series of 19 patients had a mean follow-up of 20 months (1-62). No intraoperative complication was observed. Resumption of voiding was achieved immediately postoperatively in 18 patients. One patient required more prolonged urinary drainage before voiding was restored. No cases of stent migration were observed. Postoperative serum creatinine was stable. Post-voiding residual volume was less than 100 ml in fifteen patients and less than 200 ml in four patients. One patient was explanted. The treatment of bladder neck obstruction by permanent urethral stenting is an alternative to surgery for patients considered to be temporarily or permanently inoperable. This indication remains exceptional, but should be kept in mind in view of the satisfactory medium-term results to associated with a low morbidity for a procedure performed exclusively under local anaesthesia.

(PDF emailed within 1 workday: $29.90)

Accession: 054852148

Download citation: RISBibTeXText

PMID: 17969796


Related references

The ultraflex urethral stent for the treatment of benign prostatic hyperplasia. Journal of Endourology 8(SUPPL 1): S135, 1994

A new prostatic stent for the treatment of benign prostatic hyperplasia in high-risk patients. European Urology 38(3): 272-278, 2000

Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride. Archivio Italiano di Urologia, Andrologia 87(3): 238-242, 2016

Long-term experiences with the Memotherm stent in treatment of anaesthesiological high-risk patients with benign prostatic hyperplasia. Journal of Urology 157(4 SUPPL ): 439, 1997

The use of a prostatic stent in high risk patients over 80 years old with benign prostatic hyperplasia and chronic retention. Journal of the American Geriatrics Society 42(9): 1004-1005, 1994

Medical treatment of benign prostatic hyperplasia in patients with high surgical risk. Actas Urologicas Espanolas 16(5): 417-419, 1992

Trans-urethral microwave hyperthermia in poor surgical risk patients with benign prostatic hyperplasia. Journal of Endourology 7(SUPPL 1): S109, 1993

Treatment response after transurethral microwave thermotherapy in patients with chronic urinary retention or permanent urethral catheter due to benign prostatic hyperplasia. Scandinavian Journal of Urology & Nephrology Supplementum 0(151): 40-41, 1993

Urethral stent (Memotherm(R)) for the treatment of benign prostatic hyperplasia. Acta Urologica Japonica 49(11): 645-647, 2003

Urethral stent (Memotherm) for the treatment of benign prostatic hyperplasia. Hinyokika Kiyo. Acta Urologica Japonica 49(11): 645-647, 2004

Endoscopic treatment of the benign prostatic hyperplasia with local anesthesia and sedation in patients with high surgical or anaesthesical risk. Actas Urologicas Espanolas 30(1): 46-51; Discussion 51-2, 2006

Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients. International Urology and Nephrology 40(4): 941-946, 2008

Spiral urethral prosthesis as an alternative to surgery in high risk patients with benign prostatic hyperplasia: prospective study. Journal of Urology 142(6): 1504-1506, 1989

Urodynamics and symptomatic changes after surgical treatment of symptomatic benign prostatic hyperplasia. Journal of Urology 145(4 SUPPL): 390A, 1991

Management of benign prostatic hyperplasia in high risk patients: Long-term experience with the memotherm stent. Journal of Urology 160(1): 72-76, 1998